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INTRODUCTION
Clinical and experimental studies have shown that arrhythmogenic activities originating from pulmonary veins (PV) (Haissaguerre, et al., 1998) are potential triggers in the initiation of AF (Burashnikov and Antzelevitch, 2006; Patterson, et al., 2005; Patterson, et al., 2006; Lo, et al., 2007) .
AZD1305
((tert-butyl (2-{7-[2-(4-cyano-2-fluorophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)carbamate, Figure 1 ) is a combined ion channel blocker that has undergone clinical testing for restoration and maintenance of sinus rhythm in AF patients. In vitro studies in transfected mammalian cells and ventricular cardiomyocytes show that AZD1305
predominantly blocks the rapid component of the delayed rectifying potassium current (I Kr ), the L-type calcium current and the inward sodium current, actions that all contribute to its functional effects on action potential duration, refractoriness and conduction (Andersson, et al., 2010; ). Interestingly, this ion channel-blocking profile seems to translate into atrial predominant electrophysiological actions as well as a low potential for ventricular proarrhythmia such as torsade de pointes (Andersson, et al., 2010; Burashnikov, et al., 2009; . Amiodarone is commonly used for the treatment of AF and is likely the most effective pharmacological option for maintenance of sinus rhythm. The objective of the present study was twofold. Firstly, the study was designed to evaluate the electrophysiologic and antiarrhythmic effects of AZD1305 in canine superfused PV sleeve preparations isolated from untreated dogs. Secondly, preparations isolated from dogs chronically treated with amiodarone were studied to assess potential additive or synergistic electrophysiological actions of the two compounds. Preliminary data have been presented in abstract form (Sicouri, et al., 2008b) .
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METHODS
This investigation conforms to the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication No 85-23, Revised 1996) and was approved by the Animal Care and Use Committee of the Masonic Medical Research Laboratory.
Six adult mongrel dogs were orally treated with amiodarone (40 mg/kg/day) for 6 weeks.
The dose of amiodarone used is considerably higher than the regimen typically used clinically for management of AF but falls within the range of doses previously used in dog studies (Abdollah, et al., 1990; Gallagher, et al., 1989; van Opstal, et al., 2001) . Serum concentrations of amiodarone measured using these high dosage regimens (Sicouri, et al., 1997) fell within the clinically effective concentration range (Holt, et al., 1986) , supporting the appropriateness of the high oral dosing. No signs of hypothyroidism (marked bradycardia, lethargic state, lack of appetite), hyperthyroidism (tachycardia, excitation) or lung toxicity (breathing disability) were observed over the course of the study.
In the present study untreated or chronic amiodarone-treated for 6 weeks) dogs were anticoagulated with heparin (180 IU/kg) and anesthetized with sodium pentobarbital (35 mg/kg, IV). The chest was opened via a left thoracotomy and the heart excised and placed in a cold
Superfused pulmonary vein sleeve preparation
PV sleeve preparations (approximately 2.0 x 1.5 cm) were isolated from left canine atria. (Burashnikov and Antzelevitch, 2006; Patterson, et al., 2005; Patterson, et al., 2006) , whereas sympathetic stimulation is known to lead to calcium overload, a condition responsible for the development of DADs (Chen, et al., 2000; Chen and Chen, 2006) . DADs or EADs were elicited using stimulation trains of 20 beats introduced at progressively faster rates followed by a pause. 
Effect of AZD1305 on delayed and early afterdepolarizations (DADs and EADs)
In another series of experiments we investigated the effects of AZD1305 on EADs, 
DISCUSSION
Our results indicate that in PV sleeve preparations, AZD1305 exerts potent concentrationdependent effects to depress excitability, prolong action potential duration and suppress DADinduced triggered activity. We observed a significant use-dependent decrease in V max , action potential amplitude and take-off potential and a significant increase in action potential duration.
These actions of AZD1305 are presumably secondary to its frequency-dependent blockade of the fast sodium current and the I Kr current as demonstrated in mammalian cell lines expressing the human isoforms of the ion channel proteins . In addition, the data show that in the PV sleeves isolated from the chronic amiodarone-treated dogs, AZD1305 acted synergistically to further depress excitability.
The effects of AZD1305 are similar to those described for its analogue AZD7009 which showed a high efficacy in restoring sinus rhythm in patients with long-lasting AF (Carlsson, et al., 2006; Geller, et al., 2009 ). In addition, AZD1305 has been shown to attenuate I Kr blockadeinduced APD prolongation in rabbit isolated Purkinje fibers and to widen the QRS interval and suppress dofetilide-induced torsade de pointes in anesthetized rabbits (Carlsson and Andersson, 2009; , actions attributed to its high potency in blocking the L-type calcium current and the late (persistent) sodium current. Accordingly, in the canine left ventricular wedge preparation, AZD1305 significantly increased R wave width (a surrogate measure of conduction velocity and sodium current blockade) at the highest concentration tested (10 µM) and slightly delayed repolarization but spontaneous or programmed electrical stimulation-induced proarrhythmia was never observed (Di Diego, personal communication).
Effects of AZD1305 on DAD and EAD activity in PV sleeves
This article has not been copyedited and formatted. The final version may differ from this version. Previous studies have shown that DADs and late phase EADs-induced TA can be easily induced in canine PV sleeve preparations following the addition of isoproterenol, ACh, high calcium alone or in combination (Sicouri, et al., 2008a; Sicouri, et al., 2009; Patterson, et al., 2005; Patterson, et al., 2006) , in canine and rabbit isolated single PV myocytes (Chen, et al., 2000; Chen and Chen, 2006) , and in canine coronary-perfused right atrial preparations (Burashnikov and Antzelevitch, 2006; Burashnikov and Antzelevitch, 2003) . Conditions permitting intracellular calcium loading facilitate the development of DADs and late phase 3
EADs (Burashnikov and Antzelevitch, 2006 ). The present study shows that AZD1305 is capable of suppressing DAD-induced triggered responses in PV sleeve preparations. However, late-phase 3 EADs were largely unaffected by the drug. The effects of AZD1305 on DAD-induced triggered activity are similar to those of ranolazine (Sicouri, et al., 2008a) .
Synergistic effects of amiodarone and AZD1305
In PV sleeve preparations isolated from amiodarone-treated dogs, AZD1305 markedly depresses excitability (Figure 6 ). The shortest BCL at which 1:1 activation could be maintained was dramatically increased from 420 to 1460 ms following the addition of low dose of AZD1305
(1 μ M), pointing to a synergistic effect of the drug combination. Similar synergistic usedependent depression of excitability was recently reported for the combination of chronic amiodarone and acute ranolazine in the canine isolated PV preparation (Sicouri, et al., 2010) .
Furthermore, the drug combination effectively suppressed triggered activity in the PV sleeve preparations.
The synergism of chronic amiodarone and AZD1305 may be due to their interaction with different states of the cardiac sodium channel. Amiodarone is an inactivated-state blocker of cardiac sodium channels (Whalley, et al., 1995; Kodama, et al., 1999) . If AZD1305 is a receiving amiodarone is equally safe (and effective) as the use of ibutilide alone (Fragakis, et al., 2005; Glatter, et al., 2001 ). In the canine left ventricle, long-term treatment with amiodarone differentially altered the cellular electrophysiology of the ventricular myocardium such that the transmural dispersion of repolarization decreased (Sicouri, et al., 1997) . Furthermore, amiodarone dramatically decreased the effect of d-sotalol to exaggerate dispersion of repolarization or to induce repolarization-related proarrhythmia.
In conclusion, the actions of AZD1305 to depress excitability, prolong action potential duration and eliminate TA in PV sleeve preparations may be effective in suppressing the triggers responsible for the development of AF and other atrial arrhythmias.
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